Results 51 to 60 of about 5,801 (166)

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Molnupiravir for treating COVID-19

Cochrane Database of Systematic Reviews
Five years from the start of the COVID-19 pandemic, morbidity and mortality have subsided. Vaccines have contributed to reducing the risk of infection and severe disease. However, new COVID-19 variants continue to emerge, and the role of oral antivirals such as molnupiravir in preventing progression of disease or hospitalisation must be assessed.To ...
Gayle S Tatz, Eleanor A Ochodo, Tilly Fox, Eddy J Owino, Bruce Nyagol, Priscilla Rupali, Michael McCaul, Tamara Kredo, Karen Cohen   +8 more
openaire   +2 more sources

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

Clinical and Translational Science, 2023
Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A
Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, S. Aubrey Stoch   +10 more
doaj   +1 more source

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19

Биопрепараты: Профилактика, диагностика, лечение, 2022
Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus.
E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov   +14 more
doaj   +1 more source

ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández, Karen L. Reyes‐Barrera, Sergio N. Hidalgo‐Figueroa, Edgar D. Páez‐Pérez, Clara I. Espitia Pinzón, Ángel G. Alpuche‐Solís   +5 more
wiley   +1 more source

Coronavirus M Protein Hijacks Toll‐Interacting Protein (TOLLIP) to Suppress NF‐κB Signaling and Promote Immune Evasion

MedComm, Volume 7, Issue 7, July 2026.
Under physiological conditions, pathogenic stimuli activate TLR/IL1‐R signaling, triggering TOLLIP dissociation from IRAK1 and subsequent IRAK1 phosphorylation, TRAF6 ubiquitination, and NF‐κB activation. During SARS‐CoV‐2 infection, viral M protein binds TOLLIP and stabilizes the TOLLIP–IRAK1 complex, thereby suppressing NF‐κB signaling, impairing ...
Yabin Zhang, Lu Kang, Yu Zhong, Songjun Shao, Senren Xue, Changliang Liu, Xiaoqi Zheng, Jing‐Wen Lin, Yu Chen, Fengming Luo, Huajing Wan   +10 more
wiley   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients

Clinical and Translational Science, 2022
The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau, Stephen H. Wright, Nathan J. Cherrington   +2 more
doaj   +1 more source

A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT COVID‐19 continues to be a threat to global health and a burden on healthcare systems. There is an ongoing need for COVID‐19 antiviral therapies that are safe and effective across broad patient populations. Ibuzatrelvir is a potent, selective inhibitor of the SARS‐CoV‐2 main protease and demonstrated favorable properties for clinical ...
Ravi Shankar P. Singh, Sima S. Toussi, Frances Hackman, Mona Shahbazi, John Prybylski, Siddhee A. Sahasrabudhe, Penelope Crownover, Eugene P. Kadar, Billy T. George, Negar Niki Alami, Arthur Bergman   +10 more
wiley   +1 more source

Revisiting Hydrazine Moiety as a Scaffold for the Synthesis of Potential Antiviral Pyrazole Ribonucleoside Analogues

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Three series of pyrazole ribonucleoside analogues were designed and synthesized. They were evaluated, along with some of their pronucleotides, for their antiviral activity against RNA viruses. Pyrazole ribonucleoside analogues were prepared via a linear approach starting with the reaction of D‐ribosylhydrazine with 1,3‐dicarbonyl or acrylonitrile ...
Anaïs Guillou, Nathalie Gros, Delphine Muriaux, Suzanne Peyrottes, Jean‐Jacques Vasseur, Michael Smietana, Christophe Mathé   +6 more
wiley   +1 more source